Xikui Liu, Ph.D.
Affiliations: | 2005 | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
Immunology, Cell BiologyGoogle:
"Xikui Liu"Parents
Sign in to add mentor| Sarah L. Gaffen | grad student | 2005 | SUNY Buffalo | |
| (Interleukin -17 gene regulation in T cells.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Liu X, Zawidzka EM, Li H, et al. (2019) RORγ agonists enhance the sustained antitumor activity through intrinsic Tc17 cytotoxicity and Tc1 recruitment. Cancer Immunology Research |
| Hu X, Majchrzak K, Liu X, et al. (2018) In vitro priming of adoptively transferred T cells with a RORγ agonist confers durable memory and stemness in vivo. Cancer Research |
| Hu X, Liu X, Li H, et al. (2018) Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion. Journal of Clinical Oncology. 36: 424-424 |
| Carter L, Liu X, Li H, et al. (2018) RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation. Journal of Clinical Oncology. 36: 171-171 |
| Weems GA, Hu X, Liu X, et al. (2018) Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion. Journal of Clinical Oncology. 36: 67-67 |
| Hu X, Liu X, Li H, et al. (2018) Abstract 5566: LYC-55716, a first-in-class RORγ agonist: Rationale and preclinical data to support clinical combinations with established immunotherapies Cancer Research. 78: 5566-5566 |
| Gaur P, Verma V, Nandre R, et al. (2018) Abstract 3773: RORγ agonist enhances antitumor effects of agonist anti-OX40 antibody Cancer Research. 78: 3773-3773 |
| Gaur P, Verma V, Nandre R, et al. (2018) Abstract 3762: Novel RORγt agonist induces antitumor immune effect through enhancement of tumor antigen-specific CD8+ T-cell infiltration into the TME Cancer Research. 78: 3762-3762 |
| Franchi L, Monteleone I, Hao LY, et al. (2017) Inhibiting Oxidative Phosphorylation In Vivo Restrains Th17 Effector Responses and Ameliorates Murine Colitis. Journal of Immunology (Baltimore, Md. : 1950) |
| Hu X, Liu X, Moisan J, et al. (2016) Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity. Oncoimmunology. 5: e1254854 |